Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 6/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15514433 | 0.93 | FLT4 (0.52) | FLT4KDRDGAT1PTK2JAK3 | |
| SCHEMBL15514303 | 0.93 | FLT4 (0.47) | FLT4KDRDGAT1PTK2ALK | |
| SCHEMBL15513821 | 0.92 | PTK2 (0.47) | FLT4KDRPTK2JAK3JAK2 | |
| SCHEMBL15512997 | 0.89 | PTK2 (0.46) | FLT4KDRPTK2JAK3JAK2 | |
| SCHEMBL15513314 | 0.86 | FLT4 (0.41) | FLT4KDRPTK2JAK3 | |
| SCHEMBL15524711 | 0.86 | FLT4 (0.47) | FLT4KDRDGAT1PTK2JAK3 | |
| SCHEMBL15524476 | 0.86 | FLT4 (0.50) | FLT4KDRDGAT1PTK2PRMT5 | |
| SCHEMBL15513769 | 0.85 | FLT4 (0.51) | FLT4KDRPTK2JAK3JAK2 | |
| SCHEMBL15514817 | 0.85 | PTK2 (0.48) | FLT4KDRPTK2ALK | |
| SCHEMBL15513597 | 0.85 | FLT4 (0.52) | FLT4KDRDGAT1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885DGAT1 3345/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885DGAT1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.